| Title |
MMP11 and CD2 as novel prognostic factors in hormone receptor-negative, HER2-positive breast cancer
|
|---|---|
| Published in |
Breast Cancer Research and Treatment, April 2017
|
| DOI | 10.1007/s10549-017-4234-4 |
| Pubmed ID | |
| Authors |
Jinil Han, Yoon-La Choi, Haein Kim, Jun Young Choi, Se Kyung Lee, Jeong Eon Lee, Joon-Seok Choi, Sarah Park, Jong-Sun Choi, Young Deug Kim, Seok Jin Nam, Byung-Ho Nam, Mi Jeong Kwon, Young Kee Shin |
| Abstract |
More accurate prediction of patient outcome based on molecular subtype is required to identify patients who will benefit from specific treatments. We selected novel 16 candidate prognostic genes, including 10 proliferation-related genes (p-genes) and 6 immune response-related genes (i-genes), from the gene list identified in our previous study. We then analyzed the association between their expression, measured by quantitative real-time reverse transcription-PCR in formalin-fixed, paraffin-embedded tissues, and clinical outcome in 819 breast cancer patients according to molecular subtype. The prognostic significance of clinical and gene variables varied according to the molecular subtype. Univariate analysis showed that positive lymph node status was significantly correlated with the increased risk of distant metastasis in all subtypes except the hormone receptor-negative, HER2-positive (HR-/HER2+) subtype. Most p-genes were significantly associated with poor prognosis in patients with the HR+/HER2- subtype, whereas i-genes correlated with a favorable outcome in patients with HR-/HER2+ breast cancer. In HR-/HER2+ breast cancer, four genes (three i-genes BTN3A2, CD2, and TRBC1 and the p-gene MMP11) were significantly associated with distant metastasis-free survival (DMFS). A new prognostic model for HR-/HER2+ breast cancer based on the expression of MMP11 and CD2 was developed and the DMFS for patients in the high-risk group according to our model was significantly lower than that for those in the low-risk group. Multivariate analyses revealed that our risk score is an independent prognostic factor for DMFS. Moreover, C-index showed that our risk score has a superior prognostic performance to traditional clinicopathological factors. Our new prognostic model for HR-/HER2+ breast cancer provides more accurate information on the risk of distant metastasis than traditional clinical prognostic factors and may be used to identify patients with a good prognosis in this aggressive subtype of breast cancer. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 31 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 31 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 6 | 19% |
| Other | 5 | 16% |
| Student > Bachelor | 2 | 6% |
| Student > Ph. D. Student | 2 | 6% |
| Professor | 2 | 6% |
| Other | 4 | 13% |
| Unknown | 10 | 32% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 8 | 26% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 10% |
| Medicine and Dentistry | 3 | 10% |
| Agricultural and Biological Sciences | 2 | 6% |
| Unspecified | 1 | 3% |
| Other | 3 | 10% |
| Unknown | 11 | 35% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 February 2022.
All research outputs
#7,299,930
of 23,025,074 outputs
Outputs from Breast Cancer Research and Treatment
#1,607
of 4,683 outputs
Outputs of similar age
#116,619
of 310,115 outputs
Outputs of similar age from Breast Cancer Research and Treatment
#34
of 108 outputs
Altmetric has tracked 23,025,074 research outputs across all sources so far. This one has received more attention than most of these and is in the 67th percentile.
So far Altmetric has tracked 4,683 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.2. This one has gotten more attention than average, scoring higher than 64% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 310,115 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 61% of its contemporaries.
We're also able to compare this research output to 108 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 67% of its contemporaries.